Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label safety study of PD 0332334 in generalized anxiety disorder
2008-004443-11Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imagabalin in generalized anxiety disorder (GAD), sponsored by Pfizer. Primary endpoint: Safety endpoints. Started Nov 2008; status: terminated.
02
Drugs
imagabalin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2008-004443-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004443-11.